Group 1 - The company TianKang announced that it will accept investor research from Da Cheng Fund and others between January 21 and January 22, 2026, with participation from Chairman and General Manager Zheng Hanjie and Vice General Manager and Board Secretary Li Ting [1] Group 2 - Local state-owned assets are beginning to "bottom fish" in the auction housing market, purchasing over 60 properties in the Nansha District of Guangzhou at a unit price of around 6,000 to 7,000 yuan, while the average listing price for second-hand homes in the same community exceeds 20,000 yuan [1]

Group 1: Clinical Research and Development - The company has initiated a Phase II clinical trial for CKBA cream for pediatric vitiligo, with the application accepted by the National Medical Products Administration in November 2025 [2][3]. - The exploratory study included 30 pediatric patients aged 2-12 years, showing a significant improvement in VASI scores with a 56.53% change in the treatment group compared to a 16.67% change in the control group (P=0.0029) [3]. - The Phase II clinical trial is expected to begin patient enrollment in Q2 2026, with a goal to complete it by mid-2027 [4]. Group 2: Market Potential and Demand - There are currently no approved drugs for pediatric vitiligo (ages 2-12) globally, indicating a significant unmet clinical need [5]. - The estimated market size for pediatric vitiligo treatment in China exceeds 100 billion CNY, with annual treatment costs ranging from 15,000 to 20,000 CNY per patient [6]. - CKBA is expected to achieve annual peak sales exceeding 5 billion CNY once approved for pediatric use [6]. Group 3: Additional Clinical Developments - The company has completed Phase II trials for CKBA in adult vitiligo and plans to optimize the Phase III trial protocol, with an application expected in Q1 2026 [7]. - CKBA is also being developed for other indications, including rosacea and Alzheimer's disease, with clinical trials for rosacea expected to start in Q1 2026 [7]. Group 4: Business Growth and Future Plans - The company anticipates significant revenue growth in 2026 and explosive growth in 2027, driven by the approval of several core products [8]. - Key products expected to be approved include a combination capsule of finasteride and tadalafil, and a lidocaine and prilocaine aerosol, among others [8].

证券代码：301263 证券简称：泰恩康 公告编号：2026-004 广东泰恩康医药股份有限公司 关于控股子公司 CKBA 乳膏申报儿童白癜风 获得药物临床试验批准通知书的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 广东泰恩康医药股份有限公司（以下简称"公司"）于 2025 年 11 月 20 日 在巨潮资讯网（http://www.cninfo.com.cn）披露了《关于控股子公司 CKBA 乳 膏申报儿童白癜风临床试验取得受理通知书的公告》（公告编号：2025-076）。 近日，公司控股子公司江苏博创园生物医药科技有限公司（以下简称"博创 园"）收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意博 创园提交的 CKBA 乳膏联合窄谱中波紫外线（以下简称"NB-UVB"）在 2-12 岁（含 2 岁）儿童非节段型白癜风受试者中的安全耐受性、疗效和药代动力学 特征的多中心、随机、双盲、安慰剂对照 II 期临床研究申请。现将相关情况公 告如下： 结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 11 月 19 日受理的 C ...

Group 1 - The company, 泰恩康 (301263), announced the release of share pledges by its controlling shareholders, 郑汉杰 and 孙伟文 [1] - 郑汉杰 released 4 million shares, while 孙伟文 released 2.5 million shares, totaling 6.5 million shares [1] - The released shares account for 1.53% of the company's total share capital [1]

证券代码：301263 证券简称：泰恩康 公告编号：2026-003 广东泰恩康医药股份有限公司 关于控股股东、实际控制人部分股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 广东泰恩康医药股份有限公司（以下简称"公司"）于近日收到公司控股股东、 实际控制人郑汉杰先生、孙伟文女士的通知，获悉其所持有的公司部分股份办理 了解除质押的手续，具体情况如下： 注：本公告除特别说明外，数值保留 2 位小数，数据尾差为计算时四舍五入所致。 二、股东股份累计质押情况 截至本公告披露日，上述股东及其一致行动人所持质押股份情况如下： | | | | | 占其所 | 占公司 | 已质押股份情况 | | 未质押股份情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 名称 | 持股数量 （股） | 持股 比例 | 累计被质押 股份数量 | 持股份 | 总股本 | 已质押股份 限售和冻结、 | 占已质 押股份 | 未质押股 份限售和 | 占未质 押股份 | | | | （% ...

（记者 王瀚黎） 每经头条（nbdtoutiao）——重磅数据公布：回升！专访徐洪才："内卷式竞争"得到一定缓解，下一 步"补收入"可形成良性循环 每经AI快讯，泰恩康1月21日晚间发布公告称，截至本公告日，郑汉杰累计质押股数为3550万股，占其 所持股份比例为40.17%。孙伟文累计质押股数为2177万股，占其所持股份比例为32.88%。 ...

| 权益类证券大宗交易(协议交易) | | --- | | 交易日期 | 证券代码 | 证券简称 | 成交价格 (元) | 成交量 (万股/万份) | 成交金额 (万元) | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | 2026-01-21 | 301263 | 泰恩康 | 30.40 | 10.00 | 304.00 | 国联民生证券股份 | 国联民生证券股份 | | | | | | | | 有限公司上海虹口 | 有限公司上海分公 | | | | | | | | 区杨树浦路证券营 | ロ | | | | | | | | 41 58 | | 1月21日，泰恩康大宗交易成交10万股，成交额304万元，占当日总成交额的1.28%，成交价30.4元，较 市场收盘价32.54元折价6.58%。 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 广东泰恩康医药股份有限公司（以下简称"公司"）于近日收到公司控股股 东、实际控制人孙伟文女士的通知，获悉其所持有的公司部分股份办理了质押手 续，具体情况如下： | | 是否为控 股股东或 | 本次质押 | 占其所 持股份 | 占公司 总股本 | 是否为 限售股 | 是否 为补 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 名称 | 第一大股 | 数量（股） | 比例 | 比例 | （如是， | 充质 | 质押 起始日 | 质押到 期日 | 质权人 | 质押 用途 | | | 东及其一 | | | | 注明限 | | | | | | | | 致行动人 | | （%） | （%） | 售类型） | 押 | | | | | | 孙伟文 | 是 | 8,470,000 | 12.79 | 1.99 | 否 | 否 | 2026-01-20 | 办理解 除质押 登记手 | 西藏信 托有限 | 个人 资金 ...

Market Overview - The chemical pharmaceutical sector experienced a decline of 0.77% on January 20, with Kangzhi Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 4113.65, down 0.01%, while the Shenzhen Component Index closed at 14155.63, down 0.97% [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Hanshang Group (Code: 600774) with a closing price of 11.64, up 10.02% and a trading volume of 438,600 shares, totaling 489 million yuan [1] - Tainkang (Code: 301263) with a closing price of 32.71, up 7.04% and a trading volume of 138,300 shares, totaling 437 million yuan [1] - Sitaili (Code: 603520) with a closing price of 10.58, up 2.52% and a trading volume of 210,900 shares, totaling 225 million yuan [1] - Conversely, significant decliners included: - Kangyi Pharmaceutical (Code: 300086) with a closing price of 10.44, down 5.86% and a trading volume of 447,100 shares [2] - Dizhe Pharmaceutical (Code: 688192) with a closing price of 62.72, down 5.10% and a trading volume of 42,700 shares [2] - Guangji Pharmaceutical (Code: 000952) with a closing price of 7.52, down 4.93% and a trading volume of 292,200 shares [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 1.348 billion yuan from institutional investors, while retail investors contributed a net inflow of 1.109 billion yuan [2] - The capital flow for specific stocks indicated: - Huabang Health (Code: 002004) had a net inflow of 88.38 million yuan from institutional investors, but a net outflow of 73.07 million yuan from retail investors [3] - Fuxiang Pharmaceutical (Code: 300497) recorded a net inflow of 57.88 million yuan from institutional investors, with a net outflow of 102 million yuan from retail investors [3] - Xinqiao Pharmaceutical (Code: 000756) had a net inflow of 25.08 million yuan from institutional investors, but also saw a net outflow of 15.54 million yuan from retail investors [3]

Market Overview - The Shanghai Composite Index closed at 4105.16 points, below the five-day moving average, with a decline of 0.21% [1] - The total trading volume of A-shares reached 230.22 billion yuan [1] Stocks Performance - A total of 339 A-shares have prices that broke through the five-day moving average today [1] - The stocks with the largest deviation rates include: - Meibang Technology (21.58%) - Jiayun Technology (10.57%) - Dongtong Retreat (8.25%) [1] - Stocks with smaller deviation rates that just crossed the five-day moving average include: - China Merchants Bank - Balanshi - Aike Co., Ltd. [1] Top Stocks by Deviation Rate - The top stocks with significant price increases and their respective deviation rates are: - Meibang Technology: 29.94% increase, 25.39% turnover rate, latest price 17.49 yuan [1] - Jiayun Technology: 19.92% increase, 18.95% turnover rate, latest price 6.38 yuan [1] - Dongtong Retreat: 9.78% increase, 9.36% turnover rate, latest price 2.02 yuan [1] - Other notable stocks include: - Hongmian Co., Ltd.: 10.13% increase, latest price 4.24 yuan, deviation rate 8.16% [1] - Shanghai Jiubai: 10.01% increase, latest price 14.07 yuan, deviation rate 8.11% [1]